US Environmental Protection Agency Issues Featured News Article Covering Cooperation With NanoLogix
14 November 2012 - 4:48AM
Business Wire
NanoLogix (OTC Markets: NNLX) is the subject of a featured news
article released last week by the US Environmental Protection
Agency. The article covers the progress of an ongoing Cooperative
Research and Development Agreement (CRADA) in place between the EPA
and NanoLogix. The objective of the CRADA is to develop a
comprehensive water quality test kit for use in testing drinking
and source waters in the EPA’s ten regions.
The article can be accessed on the EPA’s site at the following
link: http://www.epa.gov/nerl/features/nanologix.html
NanoLogix is pleased to announce sales experienced a significant
increase in Q3. Essentially all of Q3 and current sales have been,
and are, directly to the US Federal government or to Corporations
for use on classified US Government projects. These sales are
comprised of BNP kits and filled Petri plates. Major marketing for
BNP and BioNanoFilter (BNF) bacteria detection kits is pending
publication of two recently completed third-party studies in
peer-reviewed science journals.
The company has had increasing interest in both its BioNanoPore
(BNP) Petri-based sandwiched-membrane bacteria detection kits and
also in standard filled Petri plates, both packed in NanoLogix’s
proprietary extended-life packaging. The internally developed
patent pending packaging enables storage of both BNP and Petri for
over one year in cold storage, and for at least three months at
room temperature.
NanoLogix is honored to welcome Giles Manley, MD to the
NanoLogix Science Advisory Board (SAB). Dr. Manley brings a wealth
of medical, legal and business knowledge to the SAB.
Dr. Manley’s acceptance statement: “I am grateful for the
invitation, and very excited about being part of NanoLogix by
serving on their Science Advisory Board. What NanoLogix has
accomplished over the last several years is truly amazing. There is
no comparable system in the world that can deliver bacterial
identification as cost effectively, quickly and accurately as their
BNF and BNP product line… Through my career I have formed
acquaintances with the Chiefs of Obstetrics at some of the top
medical institutions in our country. I will make a concerted effort
to get the necessary trials started and finished at places such as
Harvard, Johns Hopkins and other institutions. I am hopeful that by
the end of 2013 the standard for GBS screening will include our
near-15 minute test at time of labor.”
More information on Dr. Manley and the SAB can be found at:
http://nanologix.com/about/team.html
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology, microbial physiology,
molecular biology, pharmacology, pharmaco-kinetics, and antibiotic
sensitivity. For more information visit: www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Sep 2023 to Sep 2024